Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8717389 | 0.96 | OPRK1 (0.79) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8717366 | 0.92 | OPRK1 (0.73) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8719776 | 0.92 | OPRK1 (0.88) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8717341 | 0.92 | OPRK1 (0.88) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8717398 | 0.92 | OPRK1 (0.88) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8720253 | 0.91 | OPRK1 (0.72) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9015325 | 0.91 | OPRK1 (0.89) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8719885 | 0.90 | OPRK1 (0.73) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8716965 | 0.89 | OPRK1 (0.69) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8719929 | 0.85 | OPRK1 (0.63) | OPRK1OPRM1OPRD1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569802-B1 | Arylacetamides | MERCK PATENT GMBH (DE) | 1998-07-15 | — | — | EP | disclosed |
| US-5532266-A | Acrylacetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| EP-0569802-A1 | Arylacetamides | MERCK PATENT GmbH (DE) | 1993-11-18 | — | — | EP | disclosed |